CRISPR-Cas Inhibiting Polypeptides

Tech ID: 32880 / UC Case 2018-166-0

Technology Description

The inventions introduce novel Cas nuclease inhibiting polypeptides with synthetic/ non-natural amino acids as well as techniques to conjugate it to an antibody or PEG for easy delivery to targeted cells. Bacterial cells respond to phage attack by activating CRISPR-Cas nuclease to digest phage genome; to escape it, phages encode anti-CRIPSR-Cas proteins. Broad-spectrum Cas enzyme inhibitors will allow for better post-translational regulation of CRISPR-Cas system for gene editing. These polypeptides were hitherto unknown and their use along with CRISPR-Cas system for genetic manipulation will improve its efficacy and potential for translation to human applications. 

Value Proposition


  • Anti-CRISPR polypeptides are the tools which will efficiently target the genes being edited
  • Large number of clinical trials are currently using CRISPR-Cas systems to treat diseases- from hematological malignancies to treating HIV via permanent genetic modifications.  However, a major risk involved in using CRISPR-Cas based gene therapy are off-target effects, which may lead to permanent changes in patient genome at non-target sites. 
  • Anti-CRISPR polypeptides allow for long-term regulation of CRISPR-Cas therapy without any off-target effects. They can be introduced independently of the CRISPR system, and they will maintain activity over longer durations.
  • Anti-CRISPR polypeptides act with a better specificity are easier to design and synthesize, when compared to small molecule inhibitors.


Related Materials

Patent Status

Country Type Number Dated Case
Japan Issued Patent 7210029 01/13/2023 2017-057
United States Of America Issued Patent 11,485,760 11/01/2022 2017-057
European Patent Office Published Application 4055158 09/04/2022 2020-001
United States Of America Published Application 20210363206 11/25/2021 2018-166

Additional Patents Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Bondy Denomy, Joseph W.
  • Doudna, Jennifer A.

Other Information


CRISPR, gene editing, Cas, anti-CRISPR

Categorized As